Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dementia l: Introduction

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correlating symptoms and skin α-synuclein seeding parameters in olfactory dysfunction and Lewy body dementia.

Journal of neurology·2026

Same author

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.

Nature medicine·2026

Same author

Simultaneous multiple post-labelling delay ASL MRI and [<sup>18</sup>F]FDG PET in a mixed memory clinic population and healthy controls.

European journal of nuclear medicine and molecular imaging·2026

Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Same author

α-Synuclein seed amplification assay in Lewy body dementia versus Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2025

Same author

[Anti-amyloid antibodies for the treatment of early-stage Alzheimer's disease].

Ugeskrift for laeger·2025

Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026

Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026

Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026

Same journal

[Fitness].

Ugeskrift for laeger·2026

Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026

Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

[Lewy body dementia].

Morten Ziebell¹, Lise Korbo, Steen G Hasselbalch

¹Neurobiologisk Forskningsenhed, Afdeling N 9201, Rigshospitalet, 2100 København Ø, Denmark. ziebell@nru.dk

Ugeskrift for Laeger

|June 8, 2010

Summary

This summary is machine-generated.

Dementia, including Lewy body dementia (DLB), is rising in Denmark. Physicians should consider DLB in elderly patients with dementia, hallucinations, and parkinsonism due to severe antipsychotic sensitivity.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 12, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Area of Science:

Neurology
Geriatrics
Pharmacology

Context:

Increasing prevalence of dementia and Lewy body dementia (DLB) in Denmark's elderly population.
High rates of antipsychotic prescriptions among elderly patients in Denmark.

Purpose:

To highlight the diagnostic importance of Lewy body dementia (DLB) in elderly patients presenting with dementia.
To emphasize the critical need for caution regarding antipsychotic use in DLB patients due to severe sensitivity.

Summary:

Elderly dementia patients with visual hallucinations, fluctuations, and parkinsonism may have Lewy body dementia (DLB).
Approximately 50% of DLB patients exhibit severe sensitivity to antipsychotics, necessitating careful consideration.
New diagnostic criteria, including dopaminergic transporter SPECT imaging, improve diagnostic accuracy for differentiating DLB.

Impact:

Enhances clinical awareness for accurate DLB diagnosis and management in elderly patients.
Aims to reduce adverse drug reactions by informing antipsychotic prescription practices.
Supports improved patient outcomes through timely and precise diagnosis and treatment strategies.